Sipucleucel-T (Provenge/) was the first FDA approved and only autologous DC loaded with prostate acid phosphatase antigen (PAP) and GM-CSF, which led to the recruitment of PAP-specific T cells into the prostate cancer microenvironment (106, 107). This evidence concerns the gene ACP3 and prostate carcinoma.